Articles related to ELECTROPHYSIOLOGY

In the OPTION trial, LAAC demonstrated a 56% reduction in bleeding events compared to oral anticoagulation while maintaining equivalent stroke prevention in post-ablation patients.

A recent randomized controlled trial found that ertugliflozin treatment was associated with a significant reduction in the yearly rate of sustained ventricular arrhythmias (3.5 vs 13.3 events) compared to placebo in patients with heart failure and implantable cardioverter-defibrillators.

Recent data shows a significant increase in pulmonary vein isolation procedures for atrial fibrillation among older adults, with concurrent decreases in complication and hospitalization rates.

The P-WCD demonstrated a clinically significant cutaneous adverse device effect rate of only 2.30%, with no severe adverse events reported, suggesting a favorable safety profile for this novel wearable defibrillator.